Cargando…

Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma

Detalles Bibliográficos
Autores principales:	Long, Georgina V, Atkinson, Victoria, Ascierto, Paolo A, Brady, Benjamin, Dutriaux, Caroline, Maio, Michele, Mortier, Laurent, Hassel, Jessica C, Rutkowski, Piotr, McNeil, Catriona, Kalinka-Warzocha, Ewa, Savage, Kerry J, Hernberg, Micaela, Lebbé, Celeste, Charles, Julie, Mihalcioiu, Catalin, Chiarion-Sileni, Vanna, Mauch, Cornelia, Schmidt, Henrik, Schadendorf, Dirk, Gogas, Helen, Horak, Christine, Sharkey, Brian, Waxman, Ian M, Robert, Caroline
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4315270/ http://dx.doi.org/10.1186/1479-5876-13-S1-O6

Ejemplares similares

Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma
por: Robert, Caroline, et al.
Publicado: (2020)

Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of BRAF-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial
por: Ascierto, Paolo A., et al.
Publicado: (2023)

Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma
por: Ascierto, Paolo Antonio, et al.
Publicado: (2020)

Pimasertib Versus Dacarbazine in Patients With Unresectable NRAS-Mutated Cutaneous Melanoma: Phase II, Randomized, Controlled Trial with Crossover
por: Lebbé, Celeste, et al.
Publicado: (2020)

Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600–Mutant Stage III Melanoma
por: Hauschild, Axel, et al.
Publicado: (2018)

Central nervous system failure in melanoma patients: results of a randomised, multicentre phase 3 study of temozolomide- and dacarbazine- based regimens
por: Chiarion-Sileni, V, et al.
Publicado: (2011)

Cutaneous Side Effects of Targeted Therapy and Immunotherapy for Advanced Melanoma
por: Russo, Irene, et al.
Publicado: (2018)

Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-α in advanced malignant melanoma
por: Daponte, Antonio, et al.
Publicado: (2013)

Consolidation electrochemotherapy with bleomycin in metastatic melanoma during treatment with dabrafenib
por: Valpione, Sara, et al.
Publicado: (2015)

Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial
por: Kirkwood, John M., et al.
Publicado: (2023)

Post first-line dacarbazine or temozolomide in neuroendocrine carcinoma
por: Couronne, Thomas, et al.
Publicado: (2020)

Safety and immunogenicity of MAGE-A3 cancer immunotherapeutic with dacarbazine in patients with MAGE-A3-positive metastatic cutaneous melanoma: an open phase I/II study with a first assessment of a predictive gene signature
por: Grob, Jean-Jacques, et al.
Publicado: (2017)

Report from the Melanoma Independent Board First Melanoma MIB Conference, 21–22 October 2013
por: Testori, A, et al.
Publicado: (2014)

Nationwide multidisciplinary consensus on the clinical management of Merkel cell carcinoma: a Delphi panel
por: Spada, Francesca, et al.
Publicado: (2022)

Dacarbazine Combined Targeted Therapy versus Dacarbazine Alone in Patients with Malignant Melanoma: A Meta-Analysis
por: Jiang, Guan, et al.
Publicado: (2014)

Meta-Analysis of the Safety and Efficacy of Interferon Combined With Dacarbazine Versus Dacarbazine Alone in Cutaneous Malignant Melanoma
por: Xin, Yong, et al.
Publicado: (2016)

Predictors of toxicity for metastatic melanoma patients treated with ipilimumab
por: Valpione, Sara, et al.
Publicado: (2015)

A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma
por: Middleton, M R, et al.
Publicado: (2000)

Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade
por: Valpione, Sara, et al.
Publicado: (2018)

Avelumab expanded access program in metastatic Merkel cell carcinoma: Efficacy and safety findings from patients in Europe and the Middle East
por: Ascierto, Paolo Antonio, et al.
Publicado: (2021)

Overall survival of patients with chemotherapy-naive advanced melanoma treated with ipilimumab 3 mg/kg in clinical trials
por: Dummer, Reinhard, et al.
Publicado: (2014)

Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial
por: Lebbé, Celeste, et al.
Publicado: (2019)

Q-TWiST analysis comparing ipilimumab/dacarbazine vs placebo/dacarbazine for patients with stage III/IV melanoma
por: Sherrill, B, et al.
Publicado: (2013)

Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600–Mutant Unresectable or Metastatic Melanoma
por: Dummer, Reinhard, et al.
Publicado: (2022)

Surgery and radiotherapy in the treatment of cutaneous melanoma
por: Testori, A., et al.
Publicado: (2009)

Treatment of metastatic malignant melanoma with dacarbazine, vindesine and cisplatin.
por: Pectasides, D., et al.
Publicado: (1989)

Survival with dacarbazine and fotemustine in newly diagnosed glioblastoma multiforme
por: Fazeny-Dörner, B, et al.
Publicado: (2003)

Dacarbazine mediates antimelanoma effects via NK cells
por: Hervieu, Alice, et al.
Publicado: (2013)

Evaluation of protective effect of amifostine on dacarbazine induced genotoxicity
por: Etebari, M., et al.
Publicado: (2015)

Dacarbazine nanoparticle topical delivery system for the treatment of melanoma
por: Hafeez, Abdul, et al.
Publicado: (2017)

Dacarbazine/doxorubicin/vinblastine: Lack of efficacy: case report
Publicado: (2022)

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
por: Wolchok, Jedd D., et al.
Publicado: (2022)

Melanoma M (Zero): Diagnosis and Therapy
por: Rastrelli, Marco, et al.
Publicado: (2013)

Investigating the Retained Inhibitory Effect of Cobimetinib against p.P124L Mutated MEK1: A Combined Liquid Biopsy and in Silico Approach
por: Catoni, Cristina, et al.
Publicado: (2022)

Pharmacokinetic results of a phase I trial of sorafenib in combination with dacarbazine in patients with advanced solid tumors
por: Brendel, Erich, et al.
Publicado: (2010)

Efficacy and safety of ipilimumab therapy in patients with metastatic melanoma: a retrospective multicenter analysis
por: Wiater, Katarzyna, et al.
Publicado: (2013)

Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis
por: Bhave, Prachi, et al.
Publicado: (2020)

Efficacy of ifosfamide, dacarbazine, doxorubicin and cisplatin in human sarcoma xenografts.
por: Budach, W., et al.
Publicado: (1994)

Synthesis and Molecular-cellular Mechanistic Study of Pyridine Derivative of Dacarbazine
por: Amirmostofian, Marzieh, et al.
Publicado: (2013)

Dacarbazine depletes the ovarian reserve in mice and depletion is enhanced with age
por: Winship, Amy L., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_k4avlv60j8g9f64m8hv5ljrq2s